{"task_id": "0036c04f824fa473", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 133/464)", "text": "atic),\n120\nInflammatory Bowel Disease Exacerbation\n\n--- Page 142 ---\nPATHOPHYSIOLOGY (CONT\u2019D)\nsevere to fulminant (failed steroid treatment,\nvery symptomatic)\n\u0002\nULCERATIVE COLITIS\nulcerative proctitis (limited\nto\nrectum),\ndistal\ncolitis/protosigmoiditis\nPATHOPHYSIOLOGY (CONT\u2019D)\n(extending up to mid sigmoid colon), left sided\ncolitis (extending up to splenic flexure), extensive\ncolitis (extending up to but not including cecum),\npancolitis (extending up to cecum)\nEXTRAINTESTINAL MANIFESTATIONS\nfever, club\nbing, uveitis, iritis, anemia, jaundice (primary sclerosing\ncholangitis), aphthous ulcers (Crohn\u2019s only), arthritis\n(spondylitis; type I arthropathy: pauciarticular and\nrelated to IBD activity; type II arthropathy: polyarticular\nand unrelated to IBD activity), erythema nodosum,\npyoderma gangrenosum, DVT, amyloidosis\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, ESR, CRP, Fe, TIBC,\nferritin, % sat, AST, ALT, ALP, bilirubin, albumin,\nCa, Mg, PO4, vitamin B12, folate\n\u0002\nMICROBIOLOGY\nstool C&S, fecal occult blood,\nstool for C. difficile toxin assay\n\u0002\nIMAGING\nAXR\n\u0002\nENDOSCOPY\nflexible sigmoidoscopy, colonoscopy\nMANAGEMENT\nSUPPORTIVE THERAPY\n\u0002\nDIET AND NUTRITION\nif mild, low fiber diet, ele\nmental diet; if severe, TPN and bowel rest\n\u0002\nANTIDIARRHEAL AGENTS\ncontraindicated in severe\nexacerbation and toxic megacolon\nANTIINFLAMMATORY AGENTS\n\u0002 5ASA SUPPOSITORIES\nif localized disease. Mesala\nmine 1 g PR qhs, glucocorticoid enema/supposi\ntories daily BID\nMANAGEMENT (CONT\u2019D)\n\u0002\nSYSTEMIC 5ASA\nfor induction and maintenance\n(sulfasalazine induction 0.5 g PO BID, then titrate\nto 0.5 1.5 g PO QID, maintenance 1 g PO BID QID;\nmesalamine 800 1600 mg PO TID maintenance\n400 800 mg PO TID; olsalazine)\n\u0002\nGLUCOCORTICOIDS\nfor flares (methylprednisolone\n30 mg IV BID, prednisone 50 mg PO daily, reduce\nby 5 mg/week)\n\u0002\nIMMUNOSUPPRESSIVE AGENTS\nazathioprine 50 mg\nPO daily, increase by 25 mg daily every 2 weeks\nto a max of 2 3 mg/kg/day as tolerated, metho\ntrexate 25 mg IM weekly\n\u0002\nANTIBIOTICS\nmetronidazole 500 mg PO TID, cipro\nfloxacin 500 mg PO BID\n\u0002\nBIOLOGICAL AGENTS\ninfliximab IV infusions of 5 mg/kg\nat 0, 2, 6 weeks. Dosing regimens differ for adalimu\nmab and certolizumab. Drug coverage for anti TNF\ntherapy differs between Canadian provinces\nSURGERY\nRelated Topics\nClostridium difficile Colitis (p. 122)\nInflammatory Arthritis (p. 282)\nDISTINGUISHING FEATURES BETWEEN CROHN\u2019S DISEASE AND ULCERATIVE COLITIS\nCrohn\u2019s disease\nUlcerative colitis\nDegree of involvement\nSegmental\nRectal sparing\nContinuous\nSymptoms\nAbd pain\nDiarrhea\nAnorexia\nPerianal disease\nBloody diarrhea\nTenesmus\nFever\nSerology\nSaccharomyces cerevisiae IgG antibody\n(sens 77%, spec 92%, PPV 82%)\nP ANCA (sens 70%, spc 88%, PPV 75%)\nPathology\nTransmural granuloma\nMucosal inflammation\nNo granuloma\nComplications\nObstruction\nStrictures\nFistulas\nFissures\nAbscesses\nColorectal cancer\nToxic megacolon (1 2%)\nColorectal cancer (1%/year after\n10 years)\nCLINICAL FEATURES\nCLINICAL FEATURES (CONT\u2019D)\nInflammatory Bowel Disease Exacerbation\n121", "text_length": 3012, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 133/464)", "type": "chunk", "chunk_index": 132, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.427485", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.429132", "status": "complete", "chunks_added": 2}